Literature DB >> 1538124

Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia.

D B Constam1, J Philipp, U V Malipiero, P ten Dijke, M Schachner, A Fontana.   

Abstract

The type beta transforming growth factors (TGF) are potent regulators of the growth and functions of lymphocytes and macrophages. Recently the human glioblastoma cell line 308 was shown to produce TGF-beta 2. The relevance of this finding was evaluated further by comparing human glioblastoma cells with their nontransformed animal counterpart, astrocytes, with regard to the production of the three TGF-beta isoforms observed so far in mammals. In this report astrocytes are demonstrated to secrete also TGF-beta 2 and to express TGF-beta 1, -beta 2, and -beta 3 mRNA in vitro. In contrast, cultured murine brain macrophages release TGF-beta 1 and are positive for TGF-beta 1 mRNA only. Glia cell-derived TGF-beta 1 and -beta 2 are detected in latent form whereas both latent and active TGF-beta are identified in the supernatant of three human glioblastoma cell lines tested. These cell lines, however, show heterogeneity in regard to the isoform of TGF-beta expressed but share with astrocytes the inability to release TGF-beta 3. Provided production and activation of latent TGF-beta occur in vivo, astrocytes and microglia may then be expected to exert regulatory influences on immune mediated diseases of the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1538124

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  96 in total

1.  Blood-brain barrier pathophysiology in traumatic brain injury.

Authors:  Adam Chodobski; Brian J Zink; Joanna Szmydynger-Chodobska
Journal:  Transl Stroke Res       Date:  2011-12       Impact factor: 6.829

2.  Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain.

Authors:  M J Schwei; P Honore; S D Rogers; J L Salak-Johnson; M P Finke; M L Ramnaraine; D R Clohisy; P W Mantyh
Journal:  J Neurosci       Date:  1999-12-15       Impact factor: 6.167

3.  Chloroquine inhibits the malignant phenotype of glioblastoma partially by suppressing TGF-beta.

Authors:  Laurent-Olivier Roy; Marie-Belle Poirier; David Fortin
Journal:  Invest New Drugs       Date:  2015-08-15       Impact factor: 3.850

4.  Neurons promote macrophage proliferation by producing transforming growth factor-beta2.

Authors:  A Dobbertin; P Schmid; M Gelman; J Glowinski; M Mallat
Journal:  J Neurosci       Date:  1997-07-15       Impact factor: 6.167

5.  Fascin-1 knock-down of human glioma cells reduces their microvilli/filopodia while improving their susceptibility to lymphocyte-mediated cytotoxicity.

Authors:  Neil T Hoa; Lisheng Ge; Kate L Erickson; Carol A Kruse; Andrew N Cornforth; Yurii Kuznetsov; Alex McPherson; Filippo Martini; Martin R Jadus
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

6.  Mechanisms of malignant glioma immune resistance and sources of immunosuppression.

Authors:  German G Gomez; Carol A Kruse
Journal:  Gene Ther Mol Biol       Date:  2006

Review 7.  Recent advances in immunobiology of brain tumors.

Authors:  M Tada; N de Tribolet
Journal:  J Neurooncol       Date:  1993-09       Impact factor: 4.130

8.  The alteration of prostaglandin E2 levels in patients with brain tumors before and after tumor removal.

Authors:  Joon-Khim Loh; Shiuh-Lin Hwang; Ann-Shung Lieu; Tzuu-Yuan Huang; Shen-Long Howng
Journal:  J Neurooncol       Date:  2002-04       Impact factor: 4.130

Review 9.  Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.

Authors:  Nikhil G Thaker; Ian F Pollack
Journal:  Expert Rev Neurother       Date:  2009-12       Impact factor: 4.618

10.  Intrathecal treatment of C6 glioma leptomeningeal metastasis in Wistar rats with interleukin-2.

Authors:  U Herrlinger; R Buchholz; P Jachimczak; M Schabet
Journal:  J Neurooncol       Date:  1996-03       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.